89. Lymphangioleiomyomatosis Clinical trials / Disease details
Clinical trials : 39 / Drugs : 46 - (DrugBank : 20) / Drug target genes : 27 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000702-29-ES (EUCTR) | 07/06/2021 | 09/02/2021 | Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM). | Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM). | EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSIS MedDRA version: 21.0;Level: PT;Classification code 10049459;Term: Lymphangioleiomyomatosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Loratadina STADA 10 mg Product Name: Loratadina Stada INN or Proposed INN: LORATADINE Other descriptive name: LORATADINE | IDIBELL (Institut d’Investigació Biomédica de Bellvitge) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 62 | Phase 2 | Spain |